Skip to content
Screener

Pre-Tax Income at other companies

Royalty Pharma logo
Royalty PharmaRPRX
$81.49M-12.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$113.38M-192%
Innoviva, Inc. logo
Innoviva, Inc.INVA
-$108.02M-249%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$11.66M+1.3%
Opko Health logo
Opko HealthOPK
-$13.4M+91.8%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$12.79M-83.4%

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886163-26-000044
Line itemThree months ended / June 30, 2026Three months ended / June 30, 2025Six months ended / June 30, 2026Six months ended / June 30, 2025
Interest expense(1,748)(1,153)(3,495)(2,020)
Other non-operating expense, net2,6821,3721,507(1,129)
Total non-operating income (expenses), net55,7132,77914,086(11,185)
Income (loss) before income taxes64,30411,22340,045(38,957)
Income tax (expense) benefit(15,796)(6,376)(4,882)1,353
Net income (loss)$48,508$4,847$35,163$(37,604)
Basic net income (loss) per share$2.42$0.25$1.76$(1.95)
Shares used in basic per share calculation20,06319,32719,97419,259

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's pre-tax income?
Ligand Pharmaceuticals (LGND) reported pre-tax income of $64.3M in Q2 2026.
How has Ligand Pharmaceuticals's pre-tax income changed year-over-year?
Ligand Pharmaceuticals's pre-tax income increased by 473.0% year-over-year, from $11.22M to $64.3M.
What is the long-term trend for Ligand Pharmaceuticals's pre-tax income?
Over 3 years (2021 to 2025), Ligand Pharmaceuticals's pre-tax income has grown at a 30.1% compound annual growth rate (CAGR), from $72.21M to $158.96M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Ligand Pharmaceuticals's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude